APXT
Apex Treasury Corporation Class A
There isn't enough reported data to score APXT yet.
BAC
Bank of America Corporation
BAC's fundamentals are strong: its operating margin rose 5 points to 35% and revenue grew 15%. At 12x earnings, it's trading in line with its usual 13x. Analysts expect earnings growth.
APXT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| N/A | |
| N/A |
APXT's profitability is currently healthy. There isn't enough data to rate its revenue. Free cash flow and net leverage aren't meaningful measures for financial services companies like APXT.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
APXT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 50x | $10.21 | — |
| Cheap | 85x | $16.96 | +66% |
| Fair | 86x | $17.10 | +68% |
| Expensive | 108x | $21.52 | +111% |
Historical ranges are pointers, not guarantees.
APXT has the edge over BAC in the historical PE scenario, which offers more potential upside but is not a forecast.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
APXT Forward outlook
There aren't enough analyst estimates for APXT to show an outlook.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
APXT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.20 | +$1.34 |
| Q2 2026 | $0.16 | +$1.29 |
| Q1 2026 | $0.12 | +$1.32 |
APXT has returned to profit: it earned $0.20 per share over the past year, after losing money the year before.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over APXT in the latest year-over-year earnings comparison.
APXT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $114.7M | -60% |
APXT's revenue has slid since its 2024 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 13% | +5.5 points |
| Q1 2025 | 3.5% | +28 points |
| Q4 2024 | 7.2% | N/A |
| Q3 2024 | 8.6% | N/A |
| Q2 2024 | -2.7% | N/A |
| Q2 2021 | -24% | N/A |
APXT's operating margin was 13% last quarter, up 15 points from the same quarter a year ago.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over APXT in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
APXT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$211.7K | -$211.7K |
| Q2 2026 | -$23.4M | -228% |
| Q1 2026 | $23M | +$24M |
| Q4 2025 | $29M | -66% |
| Q3 2025 | $0 | -100% |
| Q2 2021 | -$243 | +$210.3K |
| Q1 2021 | -$358.1K | +$24.8K |
| Q2 2020 | -$210.5K | -$210.5K |
APXT's free cash flow was $28M over the past year, down 73% from the year before. Free cash flow isn't a meaningful measure for financial services companies like APXT.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC has the edge over APXT on cash flow, with more consistent year-over-year improvement.
APXT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +33% | +11.5M shares |
| 1 year | +360% | +36M shares |
| 3 years | +3.1% | +1.4M shares |
APXT has 46M diluted shares, up 360% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $59.8M |
| Q1 2026 | $59.8M |
| Q4 2025 | — |
| Q2 2025 | $19M |
| Q1 2025 | $11.9M |
| Q4 2024 | $33.1M |
| Q3 2024 | $21.7M |
| Q2 2021 | — |
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over APXT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
APXT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2025 | -40.5x | Net Cash |
| Q1 2025 | -41.4x | Net Cash |
APXT has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like APXT.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
APXT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 75.7 | Overbought |
| Stochastic | 80.0 | Overbought |
APXT's weekly RSI is 76 (overbought) and its Stochastic is 80 (overbought).
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
APXT PE vs Financial Services Sector
| Metric | APXT | Sector median | Relative |
|---|---|---|---|
| PE | 50x | 13x | 287% above |
| PE % | 0 | 12 | 12 pts below |
APXT is trading at 50x earnings, a 287% premium to the Financial Services sector's median of 13x, though its earnings don't support one.
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over APXT on valuation relative to its sector.
APXT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.2 | 0.5% above |
| 20 week MA | $10.1 | 0.8% above |
| 50 week MA | $10.0 | 1.8% above |
APXT has stronger trend alignment. APXT is above 3 of 3 weekly averages versus BAC above 1 of 5.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
APXT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $9.89 | $9.88 | -0.1% |
| 2026 YTD | $9.88 | $10.2 | +3.3% |
APXT has the edge over BAC on returns for 2026, with the stronger performance.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.